Figure 4

Inhibition of single miRNA has no effect on entinostat-mediated downregulation of erbB2 and erbB3 in breast cancer cells. MDA-MB-453 (MDA-453) and BT474 cells were transfected with either control miRNA inhibitor no. 1 or the indicated miRNA inhibitor (60 nmol/l each). After 24 h, the cells were then untreated or treated with entinostat (1.5 μmol/l) for another 24 h. (a) Half of the cells were collected and subjected to total RNA extraction, inclusive of the small RNA fraction. The expression levels of miR-125a, miR-125b, and miR-205 were measured by qRT-PCR using TaqMan miRNA assays. RNU6B was used as an internal control. Bars, S.D. Data shows the representative of three independent experiments. (b) Another half of the cells were collected and subjected to western blot analyses with specific antibody directed against erbB2, erbB3, or β-actin